Safety Comparison# Key Differences Summary# Weight loss : Comparable (~20-21%), no head-to-head trial Mechanism : Amylin/GLP-1 (CagriSema) vs GIP/GLP-1 (tirzepatide) Molecules : Two-peptide combination vs single dual-agonist molecule Approval : Tirzepatide is FDA-approved
Dose: 0.25-0.5 mg daily (250-500 mcg) Frequency: Once daily for maintenance
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Post-transplantation diabetes mellitus
Nausea affects most people during a migraine attack and can make it hard to keep down oral medicine
Resident in various sites along the GI tract, DCs are instrumental in determining immune outcomes